- $368.55m
- $326.71m
- $79.18m
Brief: Simulations Plus Inc Releases Gastroplus Version 9.8.2
Simulations Plus Inc reports results for the quarter ended in August - Earnings Summary
Brief: Simulations Plus And The University Of Connecticut Awarded New FDA Contract To Accelerate The Development Of Long-Acting Injectable Products
Brief: Simulations Plus Reports Q4 EPS Of $0.01
Brief: Simulations Plus Receives New Grant Award From FDA
Brief: Simulations Plus Releases ADMET Predictor (X.3)
Brief: Simulations Plus Reports Continued Success In Second Phase Of Aidd Collaboration With Large Pharmaceutical Company
Brief: Simulations Plus - Received Order From Center For Drug Evaluatio Of National Medical Products Administration In China To Add Licenses To Gastroplus
U.S. STOCKS ON THE MOVE-PepsiCo, JPMorgan, Orbsat, Two Harbors Investment
Simulations Plus Inc falls on Q3 revenue miss
Simulations Plus Inc reports results for the quarter ended in February - Earnings Summary
Brief: Simulations Plus Reports Q3 Fiscal 2021 Financial Results
Simulations Plus Inc expected to post earnings of 18 cents a share - Earnings Preview
Brief: Simulations Plus Releases Ipfsym Version 1A, State-Of-The-Art Quantitative Systems Pharmacology (Qsp) Software For Idiopathic Pulmonary Fibrosis (Ipf)
Brief: Simulations Says Co's Shares Have Been Approved For Trading On Nasdaq
Brief: Simulations Plus- U.S. FDA Renews Licenses Of Dilisym Software
Brief: Simulations Plus Q2 Earnings Per Share $0.15
Brief: Simulations Plus Forms Scientific Advisory Board For Renasym Consortium
Brief: Simulations Plus Enters Agreement With Distributor In China